N85.01 Benign endometrial hyperplasia

Name of the Condition

• Benign endometrial hyperplasia

Summary

Benign endometrial hyperplasia is a condition marked by the abnormal thickening of the endometrium, the uterine lining, due to an overgrowth of cells. It is a noncancerous condition but requires evaluation to rule out precancerous changes. The condition arises from hormonal imbalances, particularly excess estrogen without sufficient progesterone, and may present with abnormal uterine bleeding.

Causes

The primary cause of benign endometrial hyperplasia is an imbalance between estrogen and progesterone, with estrogen dominance leading to uncontrolled endometrial cell growth. This imbalance can result from conditions that disrupt normal hormonal cycles, such as anovulation, or from external factors like estrogen-only hormone therapy. Unlike precancerous forms, benign hyperplasia does not involve atypical cell changes.

Risk Factors

• Obesity, which increases estrogen production
• Polycystic ovary syndrome (PCOS)
• Estrogen-only hormone therapy without progesterone
• Late menopause
• Nulliparity (never having given birth)
• Family history of endometrial or colorectal cancer
• Diabetes or insulin resistance

Symptoms

• Abnormal uterine bleeding, such as heavy or prolonged menstrual periods
• Bleeding between periods (intermenstrual bleeding)
• Postmenopausal bleeding
• Pelvic pain or pressure in some cases

Diagnosis

Diagnosis typically involves a combination of clinical evaluation and diagnostic tests. A transvaginal ultrasound may be used to assess endometrial thickness, while an endometrial biopsy is often performed to examine tissue samples for cellular changes and rule out malignancy. Hormonal assessments may also be conducted to identify underlying imbalances.

Treatment Options

Treatment focuses on addressing hormonal imbalances and managing symptoms. Progesterone therapy, either cyclic or continuous, is commonly used to counteract estrogen effects. In some cases, hormonal intrauterine devices (IUDs) may be recommended. Surgical options, such as endometrial ablation or hysterectomy, are considered for persistent or severe cases, particularly if bleeding is unresponsive to medical management.

Prognosis and Follow-Up

With appropriate treatment, benign endometrial hyperplasia generally has a good prognosis and does not progress to cancer. Regular follow-up, including periodic biopsies or imaging, may be recommended to monitor for changes. Long-term management often involves maintaining hormonal balance and addressing underlying risk factors, such as weight or metabolic conditions.

Complications

While benign by definition, untreated or poorly managed cases may lead to persistent abnormal bleeding, anemia, or, rarely, progression to more serious conditions if atypical cells are present. Complications are uncommon when the condition is properly diagnosed and treated.

Lifestyle & Prevention

• Maintain a healthy weight to reduce estrogen production
• Manage conditions like PCOS or diabetes with medical guidance
• Avoid estrogen-only hormone therapy without progesterone
• Discuss hormonal therapy options with a healthcare provider to ensure balance
• Regularly monitor menstrual patterns and report abnormalities promptly

When to Seek Professional Help

Seek medical attention if you experience abnormal uterine bleeding, such as heavy periods, bleeding between cycles, or postmenopausal bleeding. Prompt evaluation is important to rule out other conditions and initiate appropriate management. Follow up with a healthcare provider if symptoms persist or worsen despite treatment.

Tips for Medical Coders

When coding for benign endometrial hyperplasia (N85.01), ensure documentation supports the diagnosis, including clinical findings (e.g., abnormal bleeding) and diagnostic results (e.g., biopsy confirming benign changes). Differentiate from precancerous or malignant forms by verifying the absence of atypical cellular features. Document any hormonal imbalances or underlying conditions that contribute to the diagnosis to support medical necessity.